

Building Blocks, Pharmaceutical Intermediates, Chemical Reagents, Catalysts & Ligands www.ChemScene.com

## **Data Sheet**

Product Name:	5-Fluorouracil- <sup>13</sup> C, <sup>15</sup> N <sub>2</sub>	
Cat. No.:	CS-0203279	F F
CAS No.:	1189423-58-2	$H^{15}N$
Molecular Formula:	C <sub>3</sub> <sup>13</sup> CH <sub>3</sub> F <sup>15</sup> N <sub>2</sub> O <sub>2</sub>	
Molecular Weight:	133.06	13
Target:	Apoptosis; Endogenous Metabolite; HIV; Nucleoside Antimetabolite/Analog	0 <sup>-45</sup> N
Pathway:	Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Metabolic Enzyme/Protease	Н
Solubility:	10 mM in DMSO	

## **References:**

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.

[2]. Han R, et al. Amphiphilic dendritic nanomicelle-mediated co-delivery of 5-fluorouracil and NSC 123127 for enhanced therapeutic efficacy. J Drug Target. 2016 Jun 29:1-28. [Epub ahead of print]

[3]. McQuade RM, et al. Gastrointestinal dysfunction and enteric neurotoxicity following treatment with anticancer chemotherapeutic agent 5-fluorouracil. Neurogastroenterol Motil. 2016 Jun 28.

[4]. Zeng Q, et al. Knockdown of NFBD1/MDC1 enhances chemosensitivity to NSC 119875 or 5-fluorouracil in nasopharyngeal carcinoma CNE1 cells. Mol Cell Biochem. 2016 Jul418(1-2):137-46.

[5]. Yin L, et al. Antitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivo. Ther Clin Risk Manag. 2017 Feb 713:117-130.

[6]. Jones DH, et al. Ten-Year and Beyond Follow-up After Treatment With Highly Purified Liquid-Injectable Silicone for HIV-Associated Facial Lipoatrophy: A Report of 164 Patients. Dermatol Surg. 2019 Jul45(7):941-948.

[7]. Snyder SM, et al. Initial Experience with Topical Fluorouracil for Treatment of HIV-Associated Anal Intraepithelial Neoplasia. J Int Assoc Physicians AIDS Care (Chic). 201110(2):83-88.

[8]. Pek Yee Lum, et al. Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell. 2004 Jan 9116(1):121-37.

## **CAIndexNames:**

2,4(1H,3H)-Pyrimidinedione-2-13C-1,3-15N2, 5-fluoro-

## SMILES:

O=C1C(F)=C[15NH][13C]([15NH]1)=O

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 610-426-3128

Fax: 888-484-5008

-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA